Association of FOBT-assessed Faecal Hb Content with Colonic Lesions Detected in the Florence Screening Programme

Overview

Journal Br J Cancer

Specialty Oncology

Date 2007 Jan 11

PMID 17211476

Citations 29

Authors

S Ciatto

F Martinelli

G Castiglione

P Mantellini

T Rubeca

G Grazzini

A G Bonanomi

M Confortini

M Zappa

Affiliations

Soon will be listed here.

Abstract

We assessed the correlation between quantitative results of immunological faecal occult blood testing (I-FOBT) and colonic lesions (191 colorectal cancers, 890 adenomas) detected at colonoscopy in 2597 FOBT+ (cutoff 100 ng ml(-1) Hb) subjects. At univariate analysis, a higher average faecal Hb content was significantly associated with male gender (P=0.003), age (P=0.02), and colonoscopy findings (P=0.000). Among adenomas, higher faecal Hb content was significantly associated with size (P=0.0000), presence of severe dysplasia (P=0.0001), presence of villous component (P=0.0002), and location in the left colon (P=0.003). At multivariate analysis adjusting for potential confounders, age (P=0.03), size (P=0.0000), and location in the left colon (P=0.0005) were confirmed as having an independent association with higher faecal Hb content. Immunological FOBT is confirmed to be a specific screening test to detect cancer and adenoma, with a low positivity rate (3.7%) and a high positive predictive value (41.5%). Faecal Hb content is significantly higher for those lesions (cancer and high-risk adenomas) screening is aimed at detecting.

Citing Articles

Non-neoplastic findings in colon capsule endoscopy: Additional yield.

Eskemose S, Kaalby L, Deding U, Koulaouzidis A, Bjorsum-Meyer T Endosc Int Open. 2024; 12(11):E1295-E1302.

PMID: 39524194 PMC: 11543286. DOI: 10.1055/a-2438-7223.

Adenoma location, size, and morphology are risk factors for FOBT false-negative results in inpatients with advanced colorectal adenoma.

Cao X, Meng P, Liu Y, Li X, Shi X, Sun X Sci Rep. 2024; 14(1):831.

PMID: 38191805 PMC: 10774257. DOI: 10.1038/s41598-024-51377-0.

Impact of time between faecal immunochemical tests in colorectal cancer screening on screening results: A natural experiment.

Ribe S, Botteri E, Loberg M, Randel K, Kalager M, Nilsen J Int J Cancer. 2022; 152(7):1414-1424.

PMID: 36346118 PMC: 10098820. DOI: 10.1002/ijc.34351.

Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals.

Grobbee E, Wisse P, Schreuders E, van Roon A, van Dam L, Zauber A Cochrane Database Syst Rev. 2022; 6:CD009276.

PMID: 35665911 PMC: 9169237. DOI: 10.1002/14651858.CD009276.pub2.

Optimizing the colorectal cancer screening programme using faecal immunochemical test (FIT) in Flanders, Belgium from the "interval cancer" perspective.

Tran T, Peeters M, Hoeck S, Van Hal G, Janssens S, De Schutter H Br J Cancer. 2022; 126(7):1091-1099.

PMID: 35022524 PMC: 8980044. DOI: 10.1038/s41416-021-01694-2.

References

Bertario L, Russo A, Crosignani P, Sala P, Spinelli P, Pizzetti P . Reducing colorectal cancer mortality by repeated faecal occult blood test: a nested case-control study. Eur J Cancer. 1999; 35(6):973-7. DOI: 10.1016/s0959-8049(99)00062-3. View

Zorzi M, Grazzini G, Senore C, Vettorazzi M . Screening for colorectal cancer in Italy: 2004 survey. Epidemiol Prev. 2006; 30(1 Suppl 3):41-50. View

. Recommendations on cancer screening in the European union. Advisory Committee on Cancer Prevention. Eur J Cancer. 2000; 36(12):1473-8. DOI: 10.1016/s0959-8049(00)00122-2. View

Mandel J, Church T, Bond J, Ederer F, Geisser M, Mongin S . The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000; 343(22):1603-7. DOI: 10.1056/NEJM200011303432203. View

Castiglione G, Grazzini G, Miccinesi G, Rubeca T, Sani C, Turco P . Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood. J Med Screen. 2002; 9(3):99-103. DOI: 10.1136/jms.9.3.99. View

Selby J, Friedman G, Quesenberry Jr C, Weiss N . Effect of fecal occult blood testing on mortality from colorectal cancer. A case-control study. Ann Intern Med. 1993; 118(1):1-6. DOI: 10.7326/0003-4819-118-1-199301010-00001. View

Mandel J, Bond J, Church T, Snover D, Bradley G, SCHUMAN L . Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993; 328(19):1365-71. DOI: 10.1056/NEJM199305133281901. View

LANG C, Ransohoff D . Fecal occult blood screening for colorectal cancer. Is mortality reduced by chance selection for screening colonoscopy?. JAMA. 1994; 271(13):1011-3. View

Saito H, Soma Y, Koeda J, Wada T, Kawaguchi H, Sobue T . Reduction in risk of mortality from colorectal cancer by fecal occult blood screening with immunochemical hemagglutination test. A case-control study. Int J Cancer. 1995; 61(4):465-9. DOI: 10.1002/ijc.2910610406. View

10.

Castiglione G, Zappa M, Grazzini G, Mazzotta A, Biagini M, Salvadori P . Immunochemical vs guaiac faecal occult blood tests in a population-based screening programme for colorectal cancer. Br J Cancer. 1996; 74(1):141-4. PMC: 2074614. DOI: 10.1038/bjc.1996.329. View

11.

Kronborg O, Fenger C, Olsen J, Jorgensen O, Sondergaard O . Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996; 348(9040):1467-71. DOI: 10.1016/S0140-6736(96)03430-7. View

12.

Hardcastle J, Chamberlain J, Robinson M, Moss S, Amar S, Balfour T . Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996; 348(9040):1472-7. DOI: 10.1016/S0140-6736(96)03386-7. View

13.

Ederer F, Church T, Mandel J . Fecal occult blood screening in the Minnesota study: role of chance detection of lesions. J Natl Cancer Inst. 1997; 89(19):1423-8. DOI: 10.1093/jnci/89.19.1423. View

14.

Zappa M, Castiglione G, Grazzini G, Falini P, Giorgi D, Paci E . Effect of faecal occult blood testing on colorectal mortality: results of a population-based case-control study in the district of Florence, Italy. Int J Cancer. 1997; 73(2):208-10. DOI: 10.1002/(sici)1097-0215(19971009)73:2<208::aid-ijc8>3.0.co;2-#. View

15.

Castiglione G, Zappa M, Grazzini G, Sani C, Mazzotta A, Mantellini P . Cost analysis in a population based screening programme for colorectal cancer: comparison of immunochemical and guaiac faecal occult blood testing. J Med Screen. 1997; 4(3):142-6. DOI: 10.1177/096914139700400306. View

16.

Vilkin A, Rozen P, Levi Z, Waked A, Maoz E, Birkenfeld S . Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol. 2005; 100(11):2519-25. DOI: 10.1111/j.1572-0241.2005.00231.x. View

17.

Edwards J . Screening for colorectal cancer using faecal blood testing: varying the positive cut-off value. Pathology. 2005; 37(6):565-8. DOI: 10.1080/00313020500368279. View

18.

Castiglione G, Zappa M, Grazzini G, Rubeca T, Turco P, Sani C . Screening for colorectal cancer by faecal occult blood test: comparison of immunochemical tests. J Med Screen. 2000; 7(1):35-7. DOI: 10.1136/jms.7.1.35. View